New Drugs and Clinical Research · us
With surgery potentially impairing joint function, pimicotinib gains FDA approval for tenosynovial giant cell tumor
For some patients with tenosynovial giant cell tumor, removing the tumor may come at the cost of impaired mobility. The newly approved oral drug increased tumor response rates and improved pain and physical function in a randomized trial, but long-term disease control and treatment risks must also be weighed.
When a tumor affects joint movement but surgery could further impair function, treatment becomes more than a question of whether the lesion can be removed. On November 10, the U.S. Food and Drug Administration (FDA) approved the oral drug pimicotinib, marketed as Pimjetmi, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical removal could worsen functional limitations or cause severe harm, adding an option for patients facing this treatment dilemma.
The approval was based on the international, multicenter MANEUVER trial. The double-blind study randomly assigned patients in a two-to-one ratio to pimicotinib at 50 mg daily or placebo; participants were required to have measurable disease, with at least one lesion measuring two centimeters or more. The design primarily addressed whether the drug could shrink tumors and reduce disease burden in patients for whom surgery could carry substantial consequences.
At week 25, a blinded independent central review using RECIST 1.1 criteria determined that the objective response rate was 56% in the pimicotinib group and 3.2% in the placebo group. This represents a marked increase in the proportion of patients meeting predefined criteria for tumor shrinkage; it does not mean the tumors had been eradicated.
The benefits also extended beyond imaging findings. The FDA reported improvements in active range of motion in the affected joint, worst pain, and physical function; The ASCO Post further reported P values for these three comparisons of 0.0003, less than 0.0001, and 0.0074, respectively. However, these two reports on the approval did not provide complete details on the magnitude of each improvement, making it difficult for readers to judge how much practical help each patient might gain in daily activities.
How long responses last also affects the treatment's value. According to the FDA announcement, the median duration of response in the pimicotinib group had not been reached; among responders, 91% had responses lasting at least six months and 77% at least twelve months. The denominator for these percentages is patients who had responded, rather than all treated patients; the available results also cannot yet establish whether disease control can be maintained after treatment is stopped or whether treatment can reduce the need for surgery over the long term.
Alongside benefits, safety remains part of treatment considerations. Common adverse reactions include itching, rash, edema, fatigue, and nausea; the prescribing information also includes warnings for hepatotoxicity, embryo-fetal toxicity, and increased serum creatinine without an effect on renal function. The approved recommended dose is 50 mg orally daily, with or without food.
This approval translates trial evidence of tumor shrinkage and functional improvement into a treatment option for a specific adult patient population, but the trial compared the drug with placebo, so it cannot establish how it compares with other drugs. Although the application underwent collaborative review with regulators in multiple countries through Project Orbis, U.S. approval does not mean that other participating countries have reached the same decision.